ICOS and neoplasm: On the contrary the subgroup high in ICOS, the main ICOSLG receptor, harbored NOTCH pathway mutations, showed an inflamed tumor microenvironment, better prognosis, and prolonged OS with chemo-immunotherapy (HR = 0.52, <i>p</i> = 0.003).